艾迪注射液联合聚乙二醇化重组人粒细胞刺激因子注射液对弥漫大B细胞淋巴瘤化疗患者的影响

Effect of Aidi Injection Combined with Pegylated Recombinant Human Granulocyte Colony-stimulating Factor Injection in Patients with Diffuse Large B Cell Lymphoma Chemotherapy

目的:探讨艾迪注射液联合聚乙二醇化重组人粒细胞刺激因子注射液对弥漫大B细胞淋巴瘤化疗患者的影响。方法:选取2018年3月—2020年12月苏州大学附属张家港医院弥漫大B细胞淋巴瘤化疗患者100例。将其分为治疗组和对照组,各50例。两组均给予常规R-CHOP化疗方案,对照组在化疗期间给予聚乙二醇化重组人粒细胞刺激因子注射液,治疗组在对照组基础上加用艾迪注射液。比较两组化疗前后白细胞计数(WBC)及中性粒细胞计数(NE)、肝肾功能指标,安全性。结果:化疗后,治疗组WBC、NE均高于对照组,差异有统计学意义(P<0.05)。治疗组恶心呕吐和发热发生率均明显低于对照组,差异有统计学意义(P<0.05),但两组腹水和腹痛发生率比较差异均无统计学意义(P>0.05)。化疗后,治疗组天冬氨酸转氨酶(AST)水平明显低于对照组,差异有统计学意义(P<0.05),两组谷丙转氨酶(ALT)、γ-谷氨酰转肽酶(GGT)、尿酸(UA)、肾小球滤过率(GFR)水平比较差异均无统计学意义(P>0.05)。结论:对于接受R-CHOP化疗方案的弥漫大B细胞淋巴瘤患者而言,艾迪注射液联合聚乙二醇化重组人粒细胞刺激因子注射液能明显减轻WBC、NE的降低,减轻肝损伤,降低恶心呕吐、发热发生率。

Objective:To investigate the effect of Aidi Injection combined with Pegylated Recombinant Human Granulocyte Colony-stimulating Factor Injection in patients with diffuse large B cell lymphoma chemotherapy.Method:A total of 100 patients with diffuse large B-cell lymphoma who treated with chemotherapy in the Affiliated Zhangjiagang Hospital of Soochow University from March 2018 to December 2020 were selected.They were divided into treatment group and control group,50 cases in each group.Both groups were given conventional R-CHOP chemotherapy plan,the control group was given Pegylated Recombinant Human Granulocyte Colonystimulating Factor Injection during chemotherapy,and the treatment group was added Aidi Injection on the basis of the control group.The white blood cell count(WBC),neutrophil count(NE),liver and kidney function indexes before and after chemotherapy and safety were compared between two groups.Result:After chemotherapy,the WBC and NE in the treatment group were higher than those in the control group,and the differences were statistically significant(P<0.05).The incidences of nausea and vomiting and fever in the treatment group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05),but there were no significant differences in the incidences of ascites and abdominal pain between the two groups(P>0.05).After chemotherapy,the level of aspartate aminotransferase(AST)in the treatment group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).There were no significant differences in alanine aminotransferase(ALT),andγ-glutamyl transpeptidase(GGT),uric acid(UA)and glomerular filtration rate(GFR)levels between the two groups(P>0.05).Conclusion:For patients with diffuse large B cell lymphoma receiving R-CHOP chemotherapy plan,Aidi Injection combined with Pegylated Recombinant Human Granulocyte Colony-stimulating Factor can significantly reduce the decrease of WBC and NE,reduce liver injury,reduce the incidences of nausea and vomiting,and fever.